SOURCE: Bio-Rad Laboratories

Bio-Rad Laboratories

April 13, 2015 08:30 ET

Bio-Rad Extends Availability of Its Vitamin D Kit for the BioPlex 2200 System in the U.S.

HERCULES, CA--(Marketwired - Apr 13, 2015) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), today announced the launch of the BioPlex® 2200 25-OH Vitamin D kit for use on the company's BioPlex® 2200 system in U.S. markets. The assay offers a fully-automated method for the quantitative measurement of total 25-hydroxyvitamin D in human serum.

The Vitamin D testing market has seen considerable growth over the past several years. In addition to the critical role Vitamin D plays in bone health, a number of recent studies have demonstrated associations between Vitamin D deficiency and an increased risk of cardiovascular disease, autoimmune disease, and cancer. Based on data from a National Health and Nutrition Examination Survey several years ago, the CDC estimates that approximately 30% of the U.S. population has low levels of Vitamin D.

"We are pleased to extend availability of our BioPlex 2200 25-OH Vitamin D kit to U.S. markets," said John Hertia, Bio-Rad Executive Vice President and President, Clinical Diagnostics Group. "The new kit complements our already extensive menu of autoimmune and infectious disease assays for use on our BioPlex 2200 System, which offers our customers the ability to streamline their workflow in these important testing areas."

The BioPlex 2200 system is the first and only fully-automated, random access multiplex testing system, providing clinical laboratories the capability to rapidly process or "multiplex" multiple individual tests that are traditionally processed separately. The BioPlex 2200 system conserves patient sample volume, helps consolidate workstations, and simplifies workflow.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 7,600 people worldwide and had revenues exceeding $2.1 billion in 2014. For more information, please visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company cautions you not to place undue
reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

Contact Information

  • Press Contact:
    Bio-Rad Laboratories, Inc.
    Tina Cuccia
    Corporate Communications
    510-724-7000
    Email Contact